Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Comparative protection of mice against virulent and attenuated strains of Brucella abortus by passive transfer of immune T cells or serum.

Literature DB >> 2104599

Comparative protection of mice against virulent and attenuated strains of Brucella abortus by passive transfer of immune T cells or serum.

Abstract

Passively transferred immune serum provided significantly greater protection to BALB/c mice against attenuated Brucella abortus 19 than against virulent strain 2308, whether serum donors had been infected with strain 19 or 2308. In contrast, immune T cells conferred better protection upon recipients challenged with the homologous strain of B. abortus. It is hypothesized that strain 2308, but not strain 19, can survive in macrophages after opsonization and that epitopes which induce protective cell-mediated immunity may differ between strains 19 and 2308.

Entities: Disease Species

Mesh：

Substances：
Antibodies, Bacterial

Year: 1990 PMID： 2104599 PMCID： PMC258438 DOI： 10.1128/iai.58.1.254-256.1990

Source DB: PubMed Journal: Infect Immun ISSN： 0019-9567 Impact factor: 3.441

15 in total

1. Passive protection experiments with Brucella antisera.

Authors: D SULITZEANU
Journal: J Hyg (Lond) Date: 1955-06

2. Comparison of living and nonliving vaccines for Brucella abortus in BALB/c mice.

Authors: J A Montaraz; A J Winter
Journal: Infect Immun Date: 1986-08 Impact factor: 3.441

3. Inhibition of phagosome-lysosome fusion in macrophages by soluble extracts of virulent Brucella abortus.

Authors: P J Frenchick; R J Markham; A H Cochrane
Journal: Am J Vet Res Date: 1985-02 Impact factor: 1.156

4. In vivo and in vitro effects of monoclonal antibody to Ly antigens on immunity to infection.

Authors: H Pavlov; M Hogarth; I F McKenzie; C Cheers
Journal: Cell Immunol Date: 1982-07-15 Impact factor: 4.868

5. Immunity conferred upon mice by anti-LPS monoclonal antibodies in murine brucellosis.

Authors: J Limet; A M Plommet; G Dubray; M Plommet
Journal: Ann Inst Pasteur Immunol Date: 1987 May-Jun

6. Protection against Brucella abortus in mice with O-polysaccharide-specific monoclonal antibodies.

Authors: J A Montaraz; A J Winter; D M Hunter; B A Sowa; A M Wu; L G Adams
Journal: Infect Immun Date: 1986-03 Impact factor: 3.441

7. Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice.

Authors: A J Winter; G E Rowe; J R Duncan; M J Eis; J Widom; B Ganem; B Morein
Journal: Infect Immun Date: 1988-11 Impact factor: 3.441

8. Studies on the immune protection to murine experimental brucellosis conferred by Brucella fractions. I. Positive role of immune serum.

Authors: S Bascoul; A Cannat; M F Huguet; A Serre
Journal: Immunology Date: 1978-08 Impact factor: 7.397

9. Pathogenesis and cellular immunity in experimental murine brucellosis.

Authors: C Cheers
Journal: Dev Biol Stand Date: 1984

10. Immune serum-mediated effects on brucellosis evolution in mice.

Authors: M Plommet; A M Plommet
Journal: Infect Immun Date: 1983-07 Impact factor: 3.441

35 in total

1. Cloning of a Brucella melitensis group 3 antigen gene encoding Omp28, a protein recognized by the humoral immune response during human brucellosis.

Authors: L E Lindler; T L Hadfield; B D Tall; N J Snellings; F A Rubin; L L Van De Verg; D Hoover; R L Warren
Journal: Infect Immun Date: 1996-07 Impact factor: 3.441

2. A B lymphocyte mitogen is a Brucella abortus virulence factor required for persistent infection.

Authors: Juan Manuel Spera; Juan Esteban Ugalde; Juan Mucci; Diego J Comerci; Rodolfo Augusto Ugalde
Journal: Proc Natl Acad Sci U S A Date: 2006-10-19 Impact factor: 11.205

3. Immunogenicity and protective potential of a bacterially expressed recombinant dihydrolipoamide succinyltransferase (rE2o) of Brucella abortus in BALB/c mice.

Authors: Shailendra Kumar Verma; Shikha Jain; Subodh Kumar
Journal: World J Microbiol Biotechnol Date: 2012-04-22 Impact factor: 3.312

4. Characterization of specific immune responses of mice inoculated with recombinant vaccinia virus expressing an 18-kilodalton outer membrane protein of Brucella abortus.

Authors: R Vemulapalli; S Cravero; C L Calvert; T E Toth; N Sriranganathan; S M Boyle; O L Rossetti; G G Schurig
Journal: Clin Diagn Lab Immunol Date: 2000-01

5. Role of Toll-like receptor 4 in induction of cell-mediated immunity and resistance to Brucella abortus infection in mice.

Authors: Marco A Campos; Gracia M S Rosinha; Igor C Almeida; Xirlene S Salgueiro; Bruce W Jarvis; Gary A Splitter; Nilofer Qureshi; Oscar Bruna-Romero; Ricardo T Gazzinelli; Sergio C Oliveira
Journal: Infect Immun Date: 2004-01 Impact factor: 3.441

6. Carboxyl-terminal protease regulates Brucella suis morphology in culture and persistence in macrophages and mice.

Authors: Aloka B Bandara; Nammalwar Sriranganathan; Gerhardt G Schurig; Stephen M Boyle
Journal: J Bacteriol Date: 2005-08 Impact factor: 3.490

7. Comparison of immune responses and resistance to brucellosis in mice vaccinated with Brucella abortus 19 or RB51.

Authors: M G Stevens; S C Olsen; G W Pugh; D Brees
Journal: Infect Immun Date: 1995-01 Impact factor: 3.441

8. Cloning and sequencing of yajC and secD homologs of Brucella abortus and demonstration of immune responses to YajC in mice vaccinated with B. abortus RB51.

Authors: R Vemulapalli; A J Duncan; S M Boyle; N Sriranganathan; T E Toth; G G Schurig
Journal: Infect Immun Date: 1998-12 Impact factor: 3.441

9. Protective immunity to Brucella ovis in BALB/c mice following recovery from primary infection or immunization with subcellular vaccines.

Authors: M P Jiménez de Bagüés; P H Elzer; J M Blasco; C M Marín; C Gamazo; A J Winter
Journal: Infect Immun Date: 1994-02 Impact factor: 3.441

10. Brucella lumazine synthase elicits a mixed Th1-Th2 immune response and reduces infection in mice challenged with Brucella abortus 544 independently of the adjuvant formulation used.

Authors: Carlos A Velikovsky; Fernando A Goldbaum; Juliana Cassataro; Silvia Estein; Raúl A Bowden; Laura Bruno; Carlos A Fossati; Guillermo H Giambartolomei
Journal: Infect Immun Date: 2003-10 Impact factor: 3.441